Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital ...

Tempus AI (TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81.25M.

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

Tempus is acquiring Paige for $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI (TEM) has posted an impressive price move of 21% over the last week, likely influenced by a blend of recent developments. The company announced significant revenue growth in its second ...

Tesla shares zoomed nearly 5% in Friday’s midday trade amid a broader surge in stocks following Powell’s speech.

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

On fundamentals, Medtronic’s current market capitalization is $119 billion. Over the last twelve months, the company ...